3 Questions That Separate Real Medical Device Marketing Agencies From Paid Media Shops in Disguise

Key Takeaways

• Most agencies calling themselves medical device marketing agencies are digital shops with a handful of healthcare clients and no experience engineering a market.
• The 3 diagnostic questions below reveal, in under 30 minutes, whether an agency understands medtech buyer psychology or is applying pharma DTC playbooks to a B2B device.
• Stuart Simpson, CEO of THINK Surgical, spent years watching robotics companies use the same decade-old agency playbook. He took a deliberately different route.
• Medtech buyers are not consumers. A VAC committee, GPO contract, or IDN procurement cycle runs 9 to 18 months. Paid media shops built for e-commerce do not have the infrastructure for this.
• FDA clearance is the starting line, not the finish line. The agency you hire should understand which race you are running.

The right medical device marketing agency does not start with campaigns. It starts with market architecture: who the buyer is, how long the cycle runs, and whether the category you are selling into exists yet.

The three questions below are the fastest diagnostic I have found for separating a market engineering shop from a paid media shop with a healthcare logo on its About page.

Watch Stuart Simpson's full episode on The State of MedTech

Why the Agency Selection Mistake Keeps Costing Medtech Founders 12 Months

The phrase "medical device marketing agency" covers an enormous range. At one end are genuine medtech commercialization shops that understand VAC, GPO, and IDN buying committees, have worked through 12-month sales cycles, and can engineer pull-driven demand.

At the other end are digital shops that ran a campaign for a pharma brand and added "medtech" to their website.

The difference does not show up in a pitch deck. Both will show polished case studies and revenue numbers.

It shows up when your device is in the traction gap, the period between initial product validation and scalable commercial traction, and the agency is recommending A/B testing your landing page copy.

I interviewed Stuart Simpson, CEO of THINK Surgical, on an episode about their commercialization approach for the TMINI robotic system. He described something I have heard in different forms across 370 episodes of The State of MedTech:

"Nothing burns me more than when I see different robotics companies use the same playbook. That playbook is a decade old and worked when there was only one robotics company in the world. It does not work anymore."

And yet medtech founders hire agencies running exactly that playbook every quarter. The selection problem is not a due diligence failure. It is a diagnostic gap. These three questions close it.

The Buyer Architecture Question That Separates Medtech Agencies From Digital Shops

Ask this in the first meeting: who is the primary buyer for a device like mine, and what does the typical purchase cycle look like?

The right answer varies by device category and care setting. Inpatient versus outpatient versus ASC changes the buyer map entirely.

Capital equipment going into an IDN runs through a Value Analysis Committee with 9 to 18 months of clinical evidence review, budget approval, and implementation planning. Disposables into a standalone ASC can close in 60 to 90 days.

But the agency should know this distinction exists. And they should ask you about it, not the other way around.

If the agency's first instinct is to talk about physician education campaigns or HCP awareness targeting, they are mapping pharma DTC logic onto a B2B enterprise problem.

Those are push mechanisms. Medtech commercialization at scale requires engineering pull: the conditions under which the buyer committee comes to you with budget already attached.

I covered the full medical device go-to-market strategy framework in a separate post. But the buyer architecture question is the fastest single signal I know. An agency that cannot map your buyer committee in the first conversation has not done this work before.

The Market Engineering Question That No Campaign Shop Can Answer

Ask the agency to show you a market they helped engineer, not a campaign they ran.

Any agency worth hiring in medtech will have heard the terms market engineering and category design. The real test is whether they have a case study where they changed how buyers frame the problem, not just how they respond to an ad.

Campaign work is measurable: impressions, clicks, cost per lead. These are legitimate metrics for agencies that have earned them. But they sit downstream of the harder work: the market narrative that positions your device as the only logical answer to a problem the buyer already has.

The difference between a campaign and a market is this: a campaign gets someone to click. A market makes the absence of your device feel like a structural gap.

If the agency's case studies all lead with cost per acquisition or content views, they are operating in the campaign layer. That is useful for some phases of commercialization. It is not the work a pre-traction medtech startup needs from a first external marketing partner.

Neil Patel, founder of NP Digital, made a point on an episode about building a medtech-focused agency that captures the selection problem from the agency side:

"It's too competitive to be a general agency."

So the founder looking for a medical device marketing agency should ask the same question in reverse: is this agency genuinely specialized, or are they generalists with a healthcare case study on page three of their website?

For the full strategic picture on why this distinction matters, the medtech commercialization strategy post covers the architecture behind market engineering versus campaign execution.

The Traction Gap Question That Exposes Whether an Agency Understands Pre-Traction

Ask any prospective agency what their framework is for the traction gap, and when they recommend founders start engaging.

The traction gap is the period between initial product traction, meaning early clinical proof and first reference customers, and scalable, repeatable commercial performance. Most medtech startups are in this gap when they first look for an agency. And most agencies have never heard the term.

An agency that does not understand the traction gap will scope the engagement as if you are past it.

They will build a website, run some LinkedIn ads, schedule a webinar, and call that a Q1 plan. When pipeline does not materialize by Q3, they will say the product needs better positioning. That means starting over.

I covered this timing question on an episode about commercialization planning in medtech:

"We tell founders to engage us six to nine months before their commercial launch. Even longer. Because these things take time."

If the agency answers "when you're ready to scale" or "after you've hit initial traction," they are thinking about marketing as a growth layer. Market engineering is not a growth layer. It is the infrastructure that makes growth possible in the first place.

What This Means for Medtech Founders

In my experience working with medtech founders, the agency selection mistake rarely happens because founders skipped due diligence. It happens because campaign marketing vocabulary sounds identical to market engineering vocabulary until you are 90 days into an engagement that is producing reports but not pipeline.

The three questions above cut through the vocabulary layer. They force the agency to demonstrate, not describe, whether they understand the commercial architecture of medical device marketing.

FDA clearance is the starting line, not the finish line. The agency you hire needs to know which mile marker you are at.

There are agencies that do this work well. Finding them means knowing what you are looking for: not a long list of healthcare logos on a case study page, but specific answers to three diagnostic questions that reveal whether you are talking to a market engineering shop or a campaign shop that attended a medtech conference last year.

If you are evaluating whether to hire an external partner at all, the healthcare marketing agency guide covers the full framework for when that decision makes sense in medtech and what to look for.

Frequently Asked Questions

What Does a Medical Device Marketing Agency Do?

A medical device marketing agency supports the commercialization of medical devices by building market narratives, engaging clinical and economic buyers, and creating the conditions for commercial traction.

The strongest agencies go beyond campaign execution to engineer pull-driven demand, position the device within a category framework, and align commercial messaging with the specific buying architecture of the care setting.

How Do You Choose a Medical Device Marketing Agency for a Startup?

Start with three specific signals. Can the agency map your buyer architecture (VAC, GPO, IDN, or physician-direct) before pitching a tactic? Do their case studies show market engineering work, not just campaign metrics?

And is their engagement timeline built for medtech's 9 to 18-month commercialization cycles? Agencies that think in weeks are not built for medtech.

What Should a Medical Device Marketing Agency Know About Medtech Buyers?

A strong medical device marketing agency knows that medtech buyers are rarely a single person. Depending on device category, the buyer map includes a Value Analysis Committee, health system procurement, payer or GPO contract holders, and the clinical champion who advocates internally.

Agencies built for DTC or pharma typically miss this architecture and build campaigns that reach the wrong person at the wrong stage.

How Much Does a Medical Device Marketing Agency Typically Cost?

Medical device marketing agency engagements typically range from $5,000 to $25,000 per month for pre-traction startups, depending on scope. Market engineering work, including category design, clinical narrative development, and market charter creation, generally sits toward the higher end.

Campaign management and content production typically sits lower. Budget for 6 to 12 months minimum. The traction gap does not resolve in a single quarter.

Listen to Stuart Simpson's Full Story

Stuart Simpson's full conversation with Omar Khateeb is available on The State of MedTech. Watch on YouTube. Subscribe wherever you listen to podcasts.

About Stuart Simpson

Stuart Simpson is the CEO of THINK Surgical, maker of the TMINI robotic system for orthopaedic surgery. Under his leadership, THINK Surgical took a deliberately differentiated approach to commercialization in a market where most competitors were running the same decade-old agency playbooks.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.